Adenosine

Clinical trials are investigating Adenosine in several heart-related conditions, including coronary artery disease, Takotsubo syndrome, microvascular dysfunction, chronic coronary syndrome, CABG-related ischemia, and STEMI. These studies are looking at diagnostic accuracy, blood flow measures, and treatment effects in different patient groups. Most trials are in Phase 2 or Phase 3.

Table of Contents

Trial overview

These studies investigate Adenosine in heart and blood vessel research, mostly in people with coronary artery disease or related conditions.[1][2][3]

The trials are designed to study both diagnosis and treatment-related questions, depending on the condition and the study plan.[1][2]

Conditions being studied

The trial data includes coronary artery disease, Takotsubo syndrome, coronary microvascular dysfunction (also called CMD), chronic coronary syndrome, chronic angina with left ventricular dysfunction, and STEMI.[1][2][3][4][5][6][7]

One study also includes healthy subjects, so researchers can compare the heart response across different groups.[5]

Study designs and phases

All listed studies are interventional, which means the researchers give a study treatment or study procedure and then measure the results.[1][2][3][4][5][6][7]

The trials are mainly in Phase 2 and Phase 3, showing that the research is focused on testing performance, comparing strategies, and checking clinical effects in larger groups.[1][2][3][4][5][6][7]

Enrollment ranges from 30 people in a small imaging study to 1,600 people in a large treatment study, so the trials vary a lot in size.[2][3][4][5][6][7]

Main outcomes being measured

The studies measure different types of outcomes, including diagnostic sensitivity and specificity, which show how well a test finds disease and avoids false results.[1]

Other outcomes include myocardial blood flow, myocardial hyperemia, wall motion score index, left ventricular ejection fraction, ischemic burden, and thromboembolic events such as stroke, peripheral arterial embolization, or myocardial infarction.[2][3][4][5][6][7]

Some trials also use imaging methods such as PET, CMR, echocardiography, and transthoracic echocardiography to measure these outcomes.[1][3][4][5][6][7]

Who can take part

Participation depends on the study, but the target groups include people with suspected coronary artery disease, known coronary artery disease, Takotsubo syndrome, CMD, chronic coronary syndrome, chronic angina with left ventricular dysfunction, and STEMI after primary PCI.[1][2][3][4][5][6][7]

In the HYPER-trial, the study groups are split into healthy people and patients with suspected or known chronic coronary syndrome, with and without known heart failure.[5]

What the trials aim to learn

Some studies aim to see whether Adenosine helps improve the accuracy of PET imaging or quantitative blood flow measurement in the heart.[1][4]

Other studies look at whether Adenosine-based strategies can improve heart function, reduce microvascular injury, or improve clinical outcomes after heart events or surgery.[2][6][7]

Across the studies, the main goal is to learn how Adenosine can be used in different heart research settings, from diagnosis to recovery and treatment support.[1][2][3][4][5][6][7]

Trial ID Phase Condition studied Status Enrollment
2023-506971-89-00 Phase 3 Coronary artery disease Authorised 220
2022-501874-21-00 Phase 3 Takotsubo syndrome Authorised 1600
2023-507981-17-00 Phase 2 CMD Authorised 100
2023-507520-23-00 Phase 2 Coronary artery disease Authorised 30
2023-505248-20-00 Phase 3 Chronic coronary syndrome Authorised 180
2025-521325-33-00 Phase 2 Chronic angina and left ventricular dysfunction due to coronary artery disease at high risk for incomplete revascularization Completed 116
NCT06935383 Phase 2 STEMI Authorised 280

Ongoing Clinical Trials on Adenosine

  • Study on the Effects of Different Doses of Adenosine for Patients with Chronic Coronary Syndrome, with and without Heart Failure

    Recruiting

    3 1 1 1
    Investigated drugs:
    Sweden
  • Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions

    Recruiting

    3 1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Germany Italy The Netherlands Poland
  • Study on Colchicine for Patients with Angina Symptoms and Coronary Microvascular Disease

    Recruiting

    2 1 1
    Denmark
  • Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland
  • Study on the Effects of Adenosine, Dipyridamole, and Apixaban in Patients with Takotsubo Syndrome

    Recruiting

    3 1 1 1
    Denmark Norway Sweden
  • Prognostic H2[15O] PET Imaging Study in Patients with Coronary Artery Disease Using O15‑Water, Adenosine and Regadenoson

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Sweden
  • A study of tirofiban and adenosine to treat small blood vessel damage in patients with ST-elevation myocardial infarction

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    France The Netherlands Spain
  • A Study of XC001 Gene Therapy with Bypass Surgery for Patients with Coronary Artery Disease and Weakened Heart Function at Risk for Incomplete Treatment

    Not recruiting

    2 1 1
    Investigated diseases:
    Germany Hungary The Netherlands Poland

Glossary

  • Coronary artery disease: A condition where the arteries that supply blood to the heart are narrowed or blocked.
  • Takotsubo syndrome: A heart condition that can mimic a heart attack and may cause temporary weakening of the heart muscle.
  • Microvascular dysfunction: A problem with the small blood vessels of the heart, which can reduce blood flow even when the main arteries are not blocked.
  • Chronic coronary syndrome: Long-term heart symptoms caused by reduced blood flow in the coronary arteries.
  • STEMI: A type of serious heart attack called ST elevated myocardial infarction.
  • Left ventricular ejection fraction: A measure of how much blood the left side of the heart pumps out with each beat.
  • Myocardial hyperemia: Increased blood flow in the heart muscle, often measured during stress testing.
  • Myocardial blood flow reserve: How well the heart can increase blood flow when it needs more oxygen.
  • Ischemic burden: The amount of heart muscle that is not getting enough blood.
  • Microvascular obstruction: Blockage in the small blood vessels after a heart attack or related heart injury.
  • Percutaneous coronary intervention: A procedure to open narrowed heart arteries using a catheter, often called PCI.
  • Cardiac magnetic resonance imaging: A scan that creates detailed pictures of the heart and can measure blood flow and heart function.

References

  1. https://clinicaltrials.gov/study/2023-506971-89-00
  2. https://clinicaltrials.gov/study/2022-501874-21-00
  3. https://clinicaltrials.gov/study/2023-507981-17-00
  4. https://clinicaltrials.gov/study/2023-507520-23-00
  5. https://clinicaltrials.gov/study/2023-505248-20-00
  6. https://clinicaltrials.gov/study/2025-521325-33-00
  7. https://clinicaltrials.eu/trial/a-study-of-tirofiban-and-adenosine-to-treat-small-blood-vessel-damage-in-patients-with-st-elevation-myocardial-infarction/